Lin Sonia, Smith Brian S
Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, 41 Lower College Road, Fogarty Hall, Kingston, RI 02881, USA.
Crit Care Nurs Clin North Am. 2010 Sep;22(3):335-40. doi: 10.1016/j.ccell.2010.04.006.
Hepatic dysfunction in the critically ill patient presents a unique challenge to clinicians when designing pharmacotherapeutic treatment plans. Overall, the literature regarding drug dosing in critically ill patients with hepatic dysfunction is incomplete and current tools available to bedside clinicians have limitations. Despite these challenges, rational drug regimens can be implemented by critical care nurses who consider the potential impact of hepatic dysfunction on drug pharmacokinetics. This information can be applied clinically and careful monitoring plans can be implemented to assess a drug for efficacy and safety. This article reviews the pharmacokinetic changes that can occur in hepatic failure, identifies practical ways to quantify the severity of dysfunction, and discusses general drug dosing strategies in this patient population.
在为重症患者制定药物治疗方案时,肝功能障碍给临床医生带来了独特的挑战。总体而言,关于肝功能障碍重症患者药物剂量的文献并不完整,床边临床医生现有的工具也存在局限性。尽管存在这些挑战,但重症护理护士可以通过考虑肝功能障碍对药物药代动力学的潜在影响来实施合理的药物治疗方案。这些信息可应用于临床,并可实施仔细的监测计划以评估药物的疗效和安全性。本文回顾了肝衰竭时可能发生的药代动力学变化,确定了量化功能障碍严重程度的实用方法,并讨论了该患者群体的一般药物给药策略。